Advertisement

Antineoplastic drug contamination in the urine of Canadian healthcare workers

  • Chun-Yip HonEmail author
  • Kay Teschke
  • Hui Shen
  • Paul A. Demers
  • Scott Venners
Original Article

Abstract

Purpose

The purpose of this study was to quantify the urine concentration of non-metabolized cyclophosphamide (CP), a commonly administered antineoplastic drug, among potentially exposed Canadian healthcare workers and to identify factors associated with the drug concentration levels.

Methods

Participants were asked to provide two sets of 24-h urine samples (at two different sampling events), and the level of CP was quantified using high-performance liquid chromatography–tandem mass spectrometry. In addition to demographic information, participants were surveyed regarding their frequency of handling of antineoplastic drugs, safe drug handling training, and known contact with CP on their work shift. Descriptive and inferential statistical analyses were performed. A backward stepwise linear mixed effect model was conducted to identify the factors associated with urine concentration levels.

Results

We collected 201 urine samples, and 55 % (n = 111) had levels greater than the LOD of 0.05 ng/mL. The mean urinary CP concentration was 0.156 ng/mL, the geometric mean was 0.067 ng/mL, the geometric standard deviation was 3.18, the 75th percentile was 0.129 ng/mL, and the range was <LOD to 2.37 ng/mL. All eight job categories evaluated had some urinary concentrations in excess of the LOD with unit clerks having the highest average level. Workers who worked in the drug administration unit, but were not responsible for administering the drugs to patients, i.e., volunteers, oncologists, ward aides, and dieticians, had the largest proportion of samples exceeding the LOD. We did not find any correlation between the urinary concentration levels and known contact with CP during the work shift. Two factors were found to be significantly associated with urinary CP concentration: (1) Workers who had a duty to handle antineoplastic drugs had higher concentration levels, and (2) workers who had not received safe drug handling training had higher levels of CP in their urine compared with those who had.

Conclusions

The presence of non-metabolized CP in urine confirms that, despite the existence of control measures, a broad range of healthcare workers are at risk of exposure to antineoplastic drugs. A review of the effectiveness of interventions to reduce exposure is warranted and should apply to all healthcare workers involved in some capacity with the hospital medication system. This study identified two factors that are related to the urine CP concentration levels which can serve as an impetus for reducing exposure.

Keywords

Antineoplastic drugs Urinary concentration Healthcare workers Hospital medication system Risk assessment 

Notes

Acknowledgments

The authors would like to thank the WorkSafeBC Research Secretariat for funding this Project (RS2008-OG01). We also appreciate the time and cooperation of all participants and their respective facilities. We would like to recognize the assistance of the Dr. Winnie Chu from University of British Columbia who led the team responsible for sample analyses. We would like to acknowledge Jennifer Shum, Pearl Siganporia, and Sarah Chiarello who helped with sample collection efforts.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Bos PM, Brouwer DH, Stevenson H, Boogaard PJ, de Kort WL, van Hemmen JJ (1998) Proposal for the assessment of quantitative dermal exposure limits in occupational environments: part 1. Development of a concept to derive a quantitative dermal occupational exposure limit. Occup Environ Med 55(12):795–804CrossRefGoogle Scholar
  2. Burgaz S, Karahalil B, Bayrak P et al (1999) Urinary cyclophosphamide excretion and micronuclei frequencies in peripheral lymphocytes and in exfoliated buccal epithelial cells of nurses handling antineoplastics. Mutat Res 439(1):97–104CrossRefGoogle Scholar
  3. Connor TH, McDiarmid MA (2006) Preventing occupational exposures to antineoplastic drugs in health care settings. CA Cancer J Clin 56(6):354–365CrossRefGoogle Scholar
  4. Connor TH, DeBord DG, Pretty JR et al (2010) Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers. J Occup Environ Med 52(10):1019–1027CrossRefGoogle Scholar
  5. De Jonge ME, Huitema ADR, Rodenhuis S, Beijnen JH (2005) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 44(11):1135–1164CrossRefGoogle Scholar
  6. Dranitsaris G, Johnston M, Poirier S et al (2005) Are health care providers who work with cancer drugs at an increased risk for toxic events? A systematic review and meta-analysis of the literature. J Oncol Pharm Pract 11(2):69–78CrossRefGoogle Scholar
  7. Favier B, Gilles L, Desage M, Latour JF (2003) Analysis of cyclophosphamide in the urine of antineoplastic drugs handlers. Bull Cancer 90(10):905–909Google Scholar
  8. Fransman W, Vermeulen R, Kromhout H (2005) Dermal exposure to cyclophosphamide in hospitals during preparation, nursing and cleaning activities. Int Arch Occup Environ Health 78(5):403–412CrossRefGoogle Scholar
  9. Ganser GH, Hewett P (2010) An accurate substitution method for analyzing censored data. J Occup Environ Hyg 7(4):233–244CrossRefGoogle Scholar
  10. Hedmer M, Tinnerberg H, Axmon A, Joensson BAG (2008) Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Int Arch Occup Environ Health 81(7):899–911CrossRefGoogle Scholar
  11. Helsel D (2010) Much ado about next to nothing: incorporating nondetects in science. Ann Occup Hyg 54(3):257–262CrossRefGoogle Scholar
  12. Hon C-Y, Astrakianakis G, Danyluk Q, Chu WC (2011a) Pilot evaluation of dermal contamination by antineoplastic drugs among hospital pharmacy personnel. Can J Hosp Pharm 64(5):327–332Google Scholar
  13. Hon C-Y, Teschke K, Chua PPS, Venners S, Nakashima L (2011b) Occupational exposure to antineoplastic drugs: identification of job categories potentially exposed throughout the hospital medication system. Saf Health Work 2(3):273CrossRefGoogle Scholar
  14. Hon C-Y, Teschke K, Chu W, Demers P, Venners S (2013) Antineoplastic drug contamination of surfaces throughout the hospital medication system in canadian hospitals. J Occup Environ Hyg 10(7):374–383CrossRefGoogle Scholar
  15. Hon C-Y, Barzan C, Astrakianakis G (2014a) Identification of knowledge gaps regarding healthcare workers’ exposure to antineoplastic drugs: review of literature, North America versus Europe. Saf Health Work. doi: 10.1016/j.shaw.2014.06.001
  16. Hon C-Y, Teschke K, Demers PA, Venners S (2014b) Antineoplastic drug contamination on the hands of employees working throughout the hospital medication system. Ann Occup Hyg. doi: 10.1093/annhyg/meu019 Google Scholar
  17. Hornung R, Reed L (1990) Estimation of average concentration in the presence of nondetectable values. Am Ind Hyg J 5(1):46–51Google Scholar
  18. Jakubowski Marek, Trzcinka-Ochocka M (2005) Biological monitoring of exposure: trends and key developments. J Occup Health 47(1):22–48CrossRefGoogle Scholar
  19. Mason HJ, Blair S, Sams C, Jones K, Garfitt SJ, Cuschieri MJ, Baxter PJ (2005) Exposure to antineoplastic drugs in two UK hospital pharmacy units. Ann Occup Hyg 49(7):603–610CrossRefGoogle Scholar
  20. McDiarmid MA, Oliver MS, Roth TR, Rogers B, Escalante C (2010) Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs. J Occup Environ Med 52(10):1028–1034CrossRefGoogle Scholar
  21. NIOSH (2004) Preventing occupational exposure to antineoplastic and other hazardous drugs in health care settings (2004–2165). Accessed 30 Nov 2011. http://www.cdc.gov/niosh/docs/2004-165/
  22. Pethran A, Schierl R, Hauff K et al (2003) Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. Int Arch Occup Environ Health 76(1):5–10Google Scholar
  23. Ritchie MA, McAdams C, Fritz N (2000) Exposure risk in the handling and administration of chemotherapy agents: a review and synthesis of the literature. Online J Knowl Synth Nurs 7(1):51–60Google Scholar
  24. Sargent EV, Naumann BD, Dolan DG, Faria EC, Schulman L (2002) The importance of human data in the establishment of occupational exposure limits. Human Ecol Risk Assess 8:805–822CrossRefGoogle Scholar
  25. Sessink PJ, Van de Kerkhof MC, Anzion RB, Noordhoek J, Bos RP (1994) Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: is skin absorption an important exposure route? Arch Environ Health 49(3):165–169CrossRefGoogle Scholar
  26. Sottani C, Porro B, Comelli M, Imbriani M, Minoia C (2010) An analysis to study trends in occupational exposure to antineoplastic drugs among health care workers. J Chromat B 878(27):2593–2605CrossRefGoogle Scholar
  27. Sottani C, Porro B, Imbriani M, Minoia C (2011) Occupational exposure to antineoplastic drugs in four italian health care settings. Toxicol Lett 213(1):107–115CrossRefGoogle Scholar
  28. Sugiura S, Asano M, Kinoshita K, Tanimura M, Nabeshima T (2011a) Risks to health professionals from hazardous drugs in japan: a pilot study of environmental and biological monitoring of occupational exposure to cyclophosphamide. J Oncol Pharm Pract 17(1):14–19CrossRefGoogle Scholar
  29. Sugiura S, Nakanishi H, Asano M et al (2011b) Multicenter study for environmental and biological monitoring of occupational exposure to cyclophosphamide in Japan. J Oncol Pharm Pract 17(1):20–28CrossRefGoogle Scholar
  30. Suspiro A, Prista J (2011) Biomarkers of occupational exposure do anticancer agents: a minireview. Toxicol Lett 207(1):42–52CrossRefGoogle Scholar
  31. Tanimura M, Yamada K, Sugiura S et al (2009) An environmental and biological study of occupational exposure to cyclophosphamide in the pharmacy of a japanese community hospital designated for the treatment of cancer. J Health Sci 55:750–756CrossRefGoogle Scholar
  32. Turci R, Minoia C, Sottani C et al (2010) Occupational exposure to antineoplastic drugs in seven Italian hospitals: the effect of quality assurance and adherence to guidelines. J Oncol Pharm Pract 17(4):320–332CrossRefGoogle Scholar
  33. US EPA (2011) Series 875: chemical safety and pollution prevention. Accessed 26 Oct 2011. http://www.epa.gov/ocspp/pubs/frs/publications/Test_Guidelines/series875.htm
  34. Villarini M, Dominici L, Piccinini R et al (2011) Assessment of primary, oxidative and excision repaired DNA damage in hospital personnel handling antineoplastic drugs. Mutagenesis 26(3):359–369CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Chun-Yip Hon
    • 1
    • 2
    Email author
  • Kay Teschke
    • 1
  • Hui Shen
    • 1
  • Paul A. Demers
    • 3
    • 4
  • Scott Venners
    • 5
  1. 1.School of Population and Public HealthUniversity of British ColumbiaVancouverCanada
  2. 2.School of Occupational and Public HealthRyerson UniversityTorontoCanada
  3. 3.Occupational Cancer Research CentreCancer Care OntarioTorontoCanada
  4. 4.Dalla Lana School of Public HealthUniversity of TorontoTorontoCanada
  5. 5.Faculty of Health SciencesSimon Fraser UniversityBurnabyCanada

Personalised recommendations